Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity.

Quinazoline derivatives were synthesized with two steps. These derivatives induced cell apoptosis without the inhibition of EGFR activity. The novel compounds were tested in the ability of CIP2A down-regulation.